TITLE

Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease

PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." For this study the researchers selected studies if they were randomized, placebo-controlled trials of ISABAs given to patients with stable COPD. Meta-analysis showed that patients who received ISABAs had improved post-bronchodilator forced expiratory volume in 1 second, forced vital capacity, peak expiratory flow rate and breathlessness scores and fewer treatment failures compared with those who received placebo.
ACCESSION #
12104544

 

Related Articles

  • Long-Acting β2-Agonists in Asthma: Not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Meta-analysis: Anticholinergics reduce COPD exacerbations more effectively than beta-2 agonists.  // Formulary;Sep2006, Vol. 41 Issue 9, p430 

    The article reports on the results of the meta-analysis published online by the "Journal of General Internal Medicine." Researchers extracted randomized trials of the two medication classes in chronic obstructive pulmonary disease (COPD) patients. The researchers found that patients who received...

  • β-adrenoceptor agonists increase cardiovascular risk.  // Reactions Weekly;8/21/2004, Issue 1015, p5 

    Discusses research being done on cardiovascular effects of beta-agonists on patients with asthma. Reference to a study by S. R. Salpeter et al., published in the June 2004 issue of the journal "Chest"; Background on an increase in the risk of the disease; Comparison to the effectiveness of placebo.

  • A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Sovani, Milind P; Whale, Christopher I.; Tattersfield, Anne. E // Drug Safety;2004, Vol. 27 Issue 10, p689 

    The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease...

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • Budesonide/Formoterol: A Viewpoint by Michael Roth1,2. Michael Roth, Paul W. // Drugs;2004, Vol. 64 Issue 4, p443 

    This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...

  • Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease: COMMENTARY. Gibson, Peter G. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12 

    This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." COPD is defined as airflow limitation that is progressive, not fully...

  • Discussion.  // Respiratory Care;May2008, Vol. 53 Issue 5, p623 

    The article presents a discussion of the paper "Safety and Efficacy of β agonists" by James F. Donohue. Donohue says he would not use short-acting β agonists regularly in asthma or chronic obstructive pulmonary disease, because there's a lot of loss of bronchial protection. Meanwhile, he...

  • COMMENTARY. Ribas, J. // British Journal of Sports Medicine;Aor2006, Vol. 40 Issue 4, p366 

    The article comments on the paper "Use of β2 agonists in sport: are the present criteria right?," by J. Naranjo Orellana and colleagues in this issue. The findings show that the use of these drugs could provide the asthmatic athlete the chance of full breathing capacity without any extra...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics